Mr. Stefano Picone reports

CONAVI MEDICAL RETAINS BND PROJECTS INC. FOR CORPORATE DEVELOPMENT SERVICES

Conavi Medical Corp. has entered into a corporate development and strategic services agreement with BND Projects Inc.

BND will advise on corporate developments and strategic investment matters, including communications strategy and raising public awareness of Conavi and its business.

Subject to the approval of the TSX Venture Exchange, the terms of the agreement provide that the corporation will pay BND an initial one-time upfront fee of $22,500 plus a further monthly fee of $15,000 (plus HST). The contract commences on Feb. 4, 2025, for an initial term of six months and will be renewed automatically on a month-to-month basis thereafter, unless otherwise terminated by the parties in accordance with the terms thereof. BND may terminate the agreement for convenience on 30 days of notice effective six months from the commencement of the contract and Conavi may terminate the agreement for convenience on 30 days of notice effective four months from the commencement of the contract.

BND may be eligible for a grant of stock options from the corporation at a later date, though no grant of stock options is being made at this time. Any such grant of stock options will be made in accordance with TSX Venture Exchange policies.

About BND Projects Inc.

BND is a Canadian consulting firm based in the Greater Toronto Area and was founded by Christina Cameron. Ms. Cameron, a capital markets expert with over 25 years of experience in life science corporate development, will be providing the services under the agreement.

The corporation and BND act at arm's length, and BND has no present interest, directly or indirectly, in the corporation or its securities. The fees paid by the corporation to BND are for its services only.

About Conavi Medical Corp.

Conavi Medical is focused on designing, manufacturing and marketing imaging technologies to guide common minimally invasive cardiovascular procedures. Its patented Novasight Hybrid system is the first system to combine both intravascular ultrasound (IVUS) and optical coherence tomography (OCT) to enable simultaneous and co-registered imaging of coronary arteries. The Novasight Hybrid system has 510(k) clearance from the U.S. Food and Drug Administration, and regulatory approval for clinical use from Health Canada, China's National Medical Products Administration, and Japan's Ministry of Health, Labor and Welfare.

We seek Safe Harbor.